PharmiWeb.com - Global Pharma News & Resources
19-Oct-2018

Asuragen Announces New Commercial Leadership Appointment

Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced that it has hired Tom Copa as senior vice president, commercial operations. Mr. Copa will lead the global sales, marketing and customer solutions teams for Asuragen's diagnostics products business and drive strategic initiatives in their expanding genetics and oncology portfolios.

Mr. Copa joins Asuragen with extensive commercial leadership experience in health care and molecular diagnostics. He was most recently vice president of licensed technologies at the Luminex Corporation, a company that develops, manufactures, and markets biological testing technologies in the clinical diagnostic and life science industries. In total, Tom spent over 16 years at Luminex as a senior executive in roles spanning sales, marketing, and business development in their clinical and life sciences divisions. He also brings with him over seven years of direct sales experience within the medical device market at Baxter Healthcare (now a part of Cardinal Health).

“Tom is joining Asuragen to drive the expansion of our commercial team as we launch and support a rapidly expanding portfolio of kitted diagnostic products,” stated Matt McManus, M.D., Ph.D., president and CEO. “Tom’s track record of producing exceptional top and bottom line growth, along with his ability to develop high performing teams, will help us better serve both our customers and, most importantly, patients.”

Tom Copa added, “I’m delighted to be joining Asuragen at this stage of its growth as a leader in serving labs’ needs for high quality diagnostic test kits in the large and fast growing markets of genetics and oncology.”

About Asuragen

Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best-in-class diagnostic tests. For more information, visit www.asuragen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005327/en/

Editor Details

Last Updated: 19-Oct-2018